European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease

Journal of Crohn's and Colitis

Volumn 3, Issue 2, 2009, Pages 47-91

  Rahier, J F ^a   Ben Horin, S ^a   Chowers, Y ^a   Conlon, C ^a   De Munter, P ^a   D'Haens, G ^a   Domenech E ^a   Eliakim, R ^a   Eser, A ^a   Frater, J ^a   Gassull, M ^a   Giladi, M ^a   Kaser, A ^a   Lemann M ^a   Moreels, T ^a   Moschen, A ^a   Pollok, R ^a   Reinisch, W ^a   Schunter, M ^a   Stange, E F ^a   Tilg, H ^a   Van Assche, G ^a   Viget, N ^a   Vucelic, B ^a   Walsh, A ^a   Weiss, G ^a   Yazdanpanah, Y ^a   Zabana, Y ^a   Travis, S P L ^a   Colombel, J F ^a   more..

^a NONE

Author keywords

Inflammatory bowel disease; Opportunistic infections; Prevention; Vaccination

Indexed keywords

ACICLOVIR; ALPHA2B INTERFERON; AMANTADINE; AZATHIOPRINE; BCG VACCINE; CORTICOSTEROID; CYCLOSPORIN A; CYTARABINE; ETANERCEPT; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; INFLIXIMAB; METHOTREXATE; NATALIZUMAB; OSELTAMIVIR; PENCICLOVIR; PREDNISOLONE; RIBAVIRIN; RIFAXIMIN; RIMANTADINE; SILGARD; TACROLIMUS; TOPOTECAN; TUBERCULIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR; VALGANCICLOVIR; VARICELLA ZOSTER VIRUS IMMUNOGLOBULIN ANTIBODY; VIRUS VACCINE; WART VIRUS VACCINE; ZANAMIVIR;

ANTIVIRAL ACTIVITY; ANUS CARCINOMA; ASPERGILLOSIS; BCG VACCINATION; BONE MARROW TOXICITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANDIDA; CANDIDIASIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COMORBIDITY; CONSULTATION; CRYPTOCOCCUS NEOFORMANS; CYTOMEGALOVIRUS INFECTION; DEVELOPED COUNTRY; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; EMPORIATRICS; ENTERITIS; EPSTEIN BARR VIRUS; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HERPES VIRUS INFECTION; HISTOPLASMA CAPSULATUM; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INFLUENZA; INFLUENZA VIRUS; INSECT BITE; INTERVIEW; JC VIRUS; LABORATORY TEST; LEGIONELLA PNEUMOPHILA; LEGIONNAIRE DISEASE; LISTERIA MONOCYTOGENES; LISTERIOSIS; LIVER TOXICITY; MALARIA; MALNUTRITION; MYCOSIS; NOCARDIA; NOCARDIOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; PARASITOSIS; PHYSICAL EXAMINATION; PNEUMOCYSTIS JIROVECI; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SALMONELLA; SALMONELLOSIS; SCREENING; SQUAMOUS CELL CARCINOMA; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; STRONGYLOIDIASIS; TRAVELLER DIARRHEA; TREATMENT CONTRAINDICATION; TUBERCULOSIS; VACCINATION; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; WART VIRUS;

EID: 67349134712     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2009.02.010     Document Type: Review

References (402)

1. Cosnes J., Nion-Larmurier I., Beaugerie L., Afchain P., Tiret E., and Gendre J.P. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 54 (2005) 237-241
2. Rutgeerts P., Van Assche G., and Vermeire S. Review article: Infliximab therapy for inflammatory bowel disease-seven years on. Alimentary pharmacology & therapeutics 23 (2006) 451-463
3. Stange E.F., Travis S.P., Vermeire S., Beglinger C., Kupcinkas L., Geboes K., et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 55 Suppl 1 (2006) i1-15
4. Pizzo P.A. Fever in immunocompromised patients. N Engl J Med 341 (1999) 893-900
5. Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins for persons with altered immunocompetence. MMWR Recomm Rep 42 (1993) 1-18
6. Symmers W.S. Opportunistic Infections. the Concept of 'Opportunistic Infections'. Proc R Soc Med 58 (1965) 341-346
7. Korzenik J.R. Is Crohn's disease due to defective immunity?. Gut 56 (2007) 2-5
8. Marks D.J., Harbord M.W., MacAllister R., Rahman F.Z., Young J., Al-Lazikani B., et al. Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet 367 (2006) 668-678
9. Xavier R.J., and Podolsky D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448 (2007) 427-434
10. Dieckgraefe B.K., and Korzenik J.R. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet 360 (2002) 1478-1480
11. Korzenik J.R., Dieckgraefe B.K., Valentine J.F., Hausman D.F., and Gilbert M.J. Sargramostim for active Crohn's disease. N Engl J Med 352 (2005) 2193-2201
12. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., and Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. Jama 295 (2006) 2275-2285
13. Toruner M., Loftus Jr. E.V., Harmsen W.S., Zinsmeister A.R., Orenstein R., Sandborn W.J., et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 134 (2008) 929-936
14. Bernatsky S., Hudson M., and Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford) 46 (2007) 1157-1160
15. Aberra F.N., Lewis J.D., Hass D., Rombeau J.L., Osborne B., and Lichtenstein G.R. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 125 (2003) 320-327
16. Doran M.F., Crowson C.S., Pond G.R., O'Fallon W.M., and Gabriel S.E. Predictors of infection in rheumatoid arthritis. Arthritis and rheumatism 46 (2002) 2294-2300
17. Wolfe F., Caplan L., and Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis and rheumatism 54 (2006) 628-634
18. Stuck A.E., Minder C.E., and Frey F.J. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 11 (1989) 954-963
19. Kovacs J.A., and Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 342 (2000) 1416-1429
20. Risi G.F., and Tomascak V. Prevention of infection in the immunocompromised host. Am J Infect Control 26 (1998) 594-604 quiz 605-596
21. Castle S.C. Clinical relevance of age-related immune dysfunction. Clin Infect Dis 31 (2000) 578-585
22. Gavazzi G., and Krause K.H. Ageing and infection. Lancet Infect Dis 2 (2002) 659-666
23. Nikolich-Zugich J. T cell aging: naive but not young. J Exp Med 201 (2005) 837-840
24. Solana R., Pawelec G., and Tarazona R. Aging and innate immunity. Immunity 24 (2006) 491-494
25. Weng N.P. Aging of the immune system: how much can the adaptive immune system adapt?. Immunity 24 (2006) 495-499
26. Colombel J.F., Loftus Jr. E.V., Tremaine W.J., Egan L.J., Harmsen W.S., Schleck C.D., et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 126 (2004) 19-31
27. Lichtenstein G.R., Feagan B.G., Cohen R.D., Salzberg B.A., Diamond R.H., Chen D.M., et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 4 (2006) 621-630
28. Gershwin M.E., Borchers A.T., and Keen C.L. Phenotypic and functional considerations in the evaluation of immunity in nutritionally compromised hosts. J Infect Dis 182 Suppl 1 (2000) S108-S114
29. Chandra R.K. Nutrition, immunity and infection: from basic knowledge of dietary manipulation of immune responses to practical application of ameliorating suffering and improving survival. Proc Natl Acad Sci U S A 93 (1996) 14304-14307
30. Chandra R.K. Effect of vitamin and trace-element supplementation on immune responses and infection in elderly subjects. Lancet 340 (1992) 1124-1127
31. Krok K.L., and Lichtenstein G.R. Nutrition in Crohn disease. Current opinion in gastroenterology 19 (2003) 148-153
32. Ainley C., Cason J., Slavin B.M., Wolstencroft R.A., and Thompson R.P. The influence of zinc status and malnutrition on immunological function in Crohn's disease. Gastroenterology 100 (1991) 1616-1625
33. Yamamoto T., Allan R.N., and Keighley M.R. Risk factors for intra-abdominal sepsis after surgery in Crohn's disease. Dis Colon Rectum 43 (2000) 1141-1145
34. Marie I., Hachulla E., Cherin P., Hellot M.F., Herson S., Levesque H., et al. Opportunistic infections in polymyositis and dermatomyositis. Arthritis and rheumatism 53 (2005) 155-165
35. Vivarelli M., Burra P., La Barba G., Canova D., Senzolo M., Cucchetti A., et al. Influence of steroids on HCV recurrence after liver transplantation: A prospective study. J Hepatol 47 (2007) 793-798
36. Stangl J.R., Carroll K.L., Illichmann M., and Striker R. Effect of antimetabolite immunosuppressants on Flaviviridae, including hepatitis C virus. Transplantation 77 (2004) 562-567
37. Nissen M.J., Fontanges E., Allam Y., Zoulim F., Trepo C., and Miossec P. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford) 44 (2005) 1016-1020
38. Aslanidis S., Vassiliadis T., Pyrpasopoulou A., Douloumpakas I., and Zamboulis C. Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Clin Rheumatol 26 (2007) 261-264
39. Campbell S., and Ghosh S. Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 13 (2001) 191-192
40. Magliocco M.A., and Gottlieb A.B. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 51 (2004) 580-584
41. Parke F.A., and Reveille J.D. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis and rheumatism 51 (2004) 800-804
42. Vauloup C., Krzysiek R., Greangeot-Keros L., Wendling D., Goupille P., Brault R., et al. Effects of tumor necrosis factor antagonist treatment on hepatitis C-related immunological abnormalities. Eur Cytokine Netw 17 (2006) 290-293
43. Peterson J.R., Hsu F.C., Simkin P.A., and Wener M.H. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Annals of the rheumatic diseases 62 (2003) 1078-1082
44. Zein N.N. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 42 (2005) 315-322
45. Scherzer T.M., Staufer K., Novacek G., Steindl-Munda P., Schumacher S., Hofer H., et al. Efficacy and safety of antiviral therapy in patients with Crohn's disease and chronic hepatitis C. Alimentary pharmacology & therapeutics 28 6 (2008) 742-748
46. Tilg H., Vogelsang H., Ludwiczek O., Lochs H., Kaser A., Colombel J.F., et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut 52 (2003) 1728-1733
47. Beasley R.P., Hwang L.Y., Lin C.C., Leu M.L., Stevens C.E., Szmuness W., et al. Incidence of hepatitis B virus infections in preschool children in Taiwan. J Infect Dis 146 (1982) 198-204
48. Coursaget P., Yvonnet B., Chotard J., Vincelot P., Sarr M., Diouf C., et al. Age- and sex-related study of hepatitis B virus chronic carrier state in infants from an endemic area (Senegal). J Med Virol 22 (1987) 1-5
49. Stevens C.E., Beasley R.P., Tsui J., and Lee W.C. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 292 (1975) 771-774
50. Tassopoulos N.C., Papaevangelou G.J., Sjogren M.H., Roumeliotou-Karayannis A., Gerin J.L., and Purcell R.H. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology 92 (1987) 1844-1850
51. Marusawa H., Uemoto S., Hijikata M., Ueda Y., Tanaka K., Shimotohno K., et al. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 31 (2000) 488-495
52. Rehermann B., Ferrari C., Pasquinelli C., and Chisari F.V. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 2 (1996) 1104-1108
53. Yotsuyanagi H., Yasuda K., Iino S., Moriya K., Shintani Y., Fujie H., et al. Persistent viremia after recovery from self-limited acute hepatitis B. Hepatology 27 (1998) 1377-1382
54. Lok A.S., and McMahon B.J. Chronic hepatitis B. Hepatology 45 (2007) 507-539
55. Cheng A.L., Hsiung C.A., Su I.J., Chen P.J., Chang M.C., Tsao C.J., et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 37 (2003) 1320-1328
56. del Valle Garcia-Sanchez M., Gomez-Camacho F., Poyato-Gonzalez A., Iglesias-Flores E.M., de Dios-Vega J.F., and Sancho-Zapatero R. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection. Inflammatory bowel diseases 10 (2004) 701-702
57. Esteve M., Saro C., Gonzalez-Huix F., Suarez F., Forne M., and Viver J.M. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 53 (2004) 1363-1365
58. Millonig G., Kern M., Ludwiczek O., Nachbaur K., and Vogel W. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?. World J Gastroenterol 12 (2006) 974-976
59. Madonia S., Orlando A., Scimeca D., Olivo M., Rossi F., and Cottone M. Occult hepatitis B and infliximab-induced HBV reactivation. Inflammatory bowel diseases 13 (2007) 508-509
60. Lok A.S., Liang R.H., Chiu E.K., Wong K.L., Chan T.K., and Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100 (1991) 182-188
61. Yeo W., Chan P.K., Zhong S., Ho W.M., Steinberg J.L., Tam J.S., et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62 (2000) 299-307
62. Bloemena E., Weinreich S., and Schellekens P.T. The influence of prednisolone on the recirculation of peripheral blood lymphocytes in vivo. Clin Exp Immunol 80 (1990) 460-466
63. Bartlett J.G. Medical management of HIV infection. Broché Edn (2007)
64. Wallis R.S., Kalayjian R., Jacobson J.M., Fox L., Purdue L., Shikuma C.M., et al. A study of the immunology, virology, and safety of prednisone in HIV-1-infected subjects with CD4 cell counts of 200 to 700 mm(-3). J Acquir Immune Defic Syndr 32 (2003) 281-286
65. Keat A., and Rowe I. Reiter's syndrome and associated arthritides. Rheum Dis Clin North Am 17 (1991) 25-42
66. Purgus R., Tamalet C., Poignard P., Spire B., George F., Robert A., et al. Long-term nonprogressive human immunodeficiency virus-1 infection in a kidney allograft recipient. Transplantation 66 (1998) 1384-1386
67. Duh E.J., Maury W.J., Folks T.M., Fauci A.S., and Rabson A.B. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci U S A 86 (1989) 5974-5978
68. Fuchs D., Werner E.R., Dierich M.P., and Wachter H. Cell-mediated immunoreactivity in AIDS. Immunol Today 10 (1989) 150
69. Valdez H., and Lederman M.M. Cytokines and cytokine therapies in HIV infection. AIDS Clin Rev (1997) 187-228
70. Calabrese L.H., Zein N., and Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Annals of the rheumatic diseases 63 Suppl 2 (2004) ii18-ii24
71. Wallis R.S., Kyambadde P., Johnson J.L., Horter L., Kittle R., Pohle M., et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. Aids 18 (2004) 257-264
72. Beltran B., Nos P., Bastida G., Iborra M., Hoyos M., and Ponce J. Safe and effective application of anti-TNF-alpha in a patient infected with HIV and concomitant Crohn's disease. Gut 55 (2006) 1670-1671
73. Landolfo S., Gariglio M., Gribaudo G., and Lembo D. The human cytomegalovirus. Pharmacol Ther 98 (2003) 269-297
74. Taylor G.H. Cytomegalovirus. Am Fam Physician 67 (2003) 519-524
75. Slifkin M., Doron S., and Snydman D.R. Viral prophylaxis in organ transplant patients. Drugs 64 (2004) 2763-2792
76. de Jong M.D., Galasso G.J., Gazzard B., Griffiths P.D., Jabs D.A., Kern E.R., et al. Summary of the II International Symposium on Cytomegalovirus. Antiviral Res 39 (1998) 141-162
77. Kishore J., Ghoshal U., Ghoshal U.C., Krishnani N., Kumar S., Singh M., et al. Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome. J Med Microbiol 53 (2004) 1155-1160
78. Minami M., Ohta M., Ohkura T., Ando T., Ohmiya N., Niwa Y., et al. Cytomegalovirus infection in severe ulcerative colitis patients undergoing continuous intravenous cyclosporine treatment in Japan. World J Gastroenterol 13 (2007) 754-760
79. Papadakis K.A., Tung J.K., Binder S.W., Kam L.Y., Abreu M.T., Targan S.R., et al. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. The American journal of gastroenterology 96 (2001) 2137-2142
80. Kandiel A., and Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. The American journal of gastroenterology 101 (2006) 2857-2865
81. Rowshani A.T., Bemelman F.J., van Leeuwen E.M., van Lier R.A., and ten Berge I.J. Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients. Transplantation 79 (2005) 381-386
82. Berk T., Gordon S.J., Choi H.Y., and Cooper H.S. Cytomegalovirus infection of the colon: a possible role in exacerbations of inflammatory bowel disease. The American journal of gastroenterology 80 (1985) 355-360
83. Cottone M., Pietrosi G., Martorana G., Casa A., Pecoraro G., Oliva L., et al. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis. The American journal of gastroenterology 96 (2001) 773-775
84. Gehlert T., Devergne O., and Niedobitek G. Epstein-Barr virus (EBV) infection and expression of the interleukin-12 family member EBV-induced gene 3 (EBI3) in chronic inflammatory bowel disease. J Med Virol 73 (2004) 432-438
85. Goodgame R.W. Gastrointestinal cytomegalovirus disease. Ann Intern Med 119 (1993) 924-935
86. Kambham N., Vij R., Cartwright C.A., and Longacre T. Cytomegalovirus infection in steroid-refractory ulcerative colitis: a case-control study. Am J Surg Pathol 28 (2004) 365-373
87. Loftus Jr. E.V., Alexander G.L., and Carpenter H.A. Cytomegalovirus as an exacerbating factor in ulcerative colitis. J Clin Gastroenterol 19 (1994) 306-309
88. Orloff J.J., Saito R., Lasky S., and Dave H. Toxic megacolon in cytomegalovirus colitis. Am J Gastroenterol 84 (1989) 794-797
89. Streetz K.L., Buhr T., Wedemeyer H., Bleck J., Schedel I., Manns M.P., et al. Acute CMV-colitis in a patient with a history of ulcerative colitis. Scand J Gastroenterol 38 (2003) 119-122
90. Vega R., Bertran X., Menacho M., Domenech E., Moreno de Vega V., Hombrados M., et al. Cytomegalovirus infection in patients with inflammatory bowel disease. Am J Gastroenterol 94 (1999) 1053-1056
91. Wakefield A.J., Fox J.D., Sawyerr A.M., Taylor J.E., Sweenie C.H., Smith M., et al. Detection of herpesvirus DNA in the large intestine of patients with ulcerative colitis and Crohn's disease using the nested polymerase chain reaction. J Med Virol 38 (1992) 183-190
92. Dimitroulia E., Spanakis N., Konstantinidou A.E., Legakis N.J., and Tsakris A. Frequent detection of cytomegalovirus in the intestine of patients with inflammatory bowel disease. Inflammatory bowel diseases 12 (2006) 879-884
93. Matsuoka K., Iwao Y., Mori T., Sakuraba A., Yajima T., Hisamatsu T., et al. Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients. Am J Gastroenterol 102 (2007) 331-337
94. Lavagna A., Bergallo M., Daperno M., Sostegni R., Costa C., Leto R., et al. Infliximab and the risk of latent viruses reactivation in active Crohn's disease. Inflammatory bowel diseases 13 (2007) 896-902
95. Scheinberg P., Fischer S.H., Li L., Nunez O., Wu C.O., Sloand E.M., et al. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood 109 (2007) 3219-3224
96. Torre-Cisneros J., Del Castillo M., Caston J.J., Castro M.C., Perez V., and Collantes E. Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis. Rheumatology (Oxford) 44 (2005) 1132-1135
97. Gerna G., Zavattoni M., Percivalle E., Zella D., Torsellini M., and Revello M.G. Diagnosis of human cytomegalovirus infections in the immunocompromised host. Clin Diagn Virol 5 (1996) 181-186
98. Haerter G., Manfras B.J., de Jong-Hesse Y., Wilts H., Mertens T., Kern P., et al. Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid arthritis. Clin Infect Dis 39 (2004) e88-e94
99. Fatahzadeh M., and Schwartz R.A. Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management. J Am Acad Dermatol 57 (2007) 737-763 quiz 764-736
100. Gupta R., Warren T., and Wald A. Genital herpes. Lancet 370 (2007) 2127-2137
101. Alimohamadi S.M., Malekzadeh R., Mirmadjless S.H., Mohamadnejad M., and Zamani F. Herpes simplex virus encephalitis during immunosuppressive treatment of ulcerative colitis. Med Gen Med 6 (2004) 7
102. el-Serag H.B., Zwas F.R., Cirillo N.W., and Eisen R.N. Fulminant herpes colitis in a patient with Crohn's disease. J Clin Gastroenterol 22 (1996) 220-223
103. Shlien R.D., Meyers S., Lee J.A., Dische R., and Janowitz H.D. Fulminant herpes simplex hepatitis in a patient with ulcerative colitis. Gut 29 (1988) 257-261
104. Taplitz R.A., and Jordan M.C. Pneumonia caused by herpesviruses in recipients of hematopoietic cell transplants. Semin Respir Infect 17 (2002) 121-129
105. Wolfsen H.C., Bolen J.W., Bowen J.L., and Fenster L.F. Fulminant herpes hepatitis mimicking hepatic abscesses. J Clin Gastroenterol 16 (1993) 61-64
106. Schunter M. Herpes simplex colitis complicating ulcerative colitis: a case report and brief review on superinfections. JCC 1 (2007) 41-46
107. Fillet A.M. Prophylaxis of herpesvirus infections in immunocompetent and immunocompromised older patients. Drugs Aging 19 (2002) 343-354
108. Martinez V., Caumes E., and Chosidow O. Treatment to prevent recurrent genital herpes. Curr Opin Infect Dis 21 (2008) 42-48
109. Whitley R.J., and Gnann Jr. J.W. Acyclovir: a decade later. N Engl J Med 327 (1992) 782-789
110. Listing J., Strangfeld A., Kary S., Rau R., von Hinueber U., Stoyanova-Scholz M., et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis and rheumatism 52 (2005) 3403-3412
111. Blaszyk H., Hyman N.H., and Cooper K. Herpes simplex virus colitis in ulcerative colitis, simulating malignancy. Histopathology 49 (2006) 316-318
112. Smith J.S., and Robinson N.J. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis 186 Suppl 1 (2002) S3-S28
113. Ruther U., Nunnensiek C., Muller H.A., Rupp W., Gforer S., Bader H., et al. Herpes simplex-associated exacerbation of Crohn's disease. Successful treatment with acyclovir. Dtsch Med Wochenschr 117 (1992) 46-50
114. Liebau P., Kuse E., Winkler M., Schlitt H.J., Oldhafer K., Verhagen W., et al. Management of herpes simplex virus type 1 pneumonia following liver transplantation. Infection 24 (1996) 130-135
115. Arvin A.M. Varicella-zoster virus. Clin Microbiol Rev 9 (1996) 361-381
116. Hambleton S., and Gershon A.A. Preventing varicella-zoster disease. Clin Microbiol Rev 18 (2005) 70-80
117. Sands B.E., Cuffari C., Katz J., Kugathasan S., Onken J., Vitek C., et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflammatory bowel diseases 10 (2004) 677-692
118. Marin M., Guris D., Chaves S.S., Schmid S., and Seward J.F. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56 (2007) 1-40
119. Aberra F.N., and Lichtenstein G.R. Methods to avoid infections in patients with inflammatory bowel disease. Inflammatory bowel diseases 11 (2005) 685-695
120. Antonelli M.A., Moreland L.W., and Brick J.E. Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. Am J Med 90 (1991) 295-298
121. Kinder A., Stephens S., Mortimer N., and Sheldon P. Severe herpes zoster after infliximab infusion. Postgrad Med J 80 (2004) 26
122. Soon S.Y., Ansari A., Yaneza M., Raoof S., Hirst J., and Sanderson J.D. Experience with the use of low-dose methotrexate for inflammatory bowel disease. Eur J Gastroenterol Hepatol 16 (2004) 921-926
123. Stephens M.C., Shepanski M.A., Mamula P., Markowitz J.E., Brown K.A., and Baldassano R.N. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol 98 (2003) 104-111
124. van der Veen M.J., van der Heide A., Kruize A.A., and Bijlsma J.W. Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Annals of the rheumatic diseases 53 (1994) 224-228
125. Deutsch D.E., Olson A.D., Kraker S., and Dickinson C.J. Overwhelming varicella pneumonia in a patient with Crohn's disease treated with 6-mercaptopurine. J Pediatr Gastroenterol Nutr 20 (1995) 351-353
126. Leung V.S., Nguyen M.T., and Bush T.M. Disseminated primary varicella after initiation of infliximab for Crohn's disease. Am J Gastroenterol 99 (2004) 2503-2504
127. Vergara M., Brullet E., Campo R., Calvet X., and Blanch L. Fulminant infection caused by varicella herpes zoster in patient with Crohn disease undergoing treatment with azathioprine. Gastroenterol Hepatol 24 (2001) 47
128. Arias M., Arias-Rivas S., Dapena D., and Mera A. Brachial plexitis and myelitis and herpes-zoster lumbar plexus disorder in patient treated with infliximab. Neurologia 20 (2005) 374-376
129. Ching D.W. Severe, disseminated, life threatening herpes zoster infection in a patient with rheumatoid arthritis treated with methotrexate. Annals of the rheumatic diseases 54 (1995) 155
130. Choi H.J., Kim M.Y., Kim H.O., and Park Y.M. An atypical varicella exanthem associated with the use of infliximab. Int J Dermatol 45 (2006) 999-1000
131. Golden H.E. Herpes zoster encephalomyelitis in a patient with rheumatoid arthritis treated with low dose methotrexate. J Rheumatol 24 (1997) 2487-2488
132. Korelitz B.I., Fuller S.R., Warman J.I., and Goldberg M.D. Shingles during the course of treatment with 6-mercaptopurine for inflammatory bowel disease. Am J Gastroenterol 94 (1999) 424-426
133. Lemyze M., Tavernier J.Y., Chevalon B., and Lamblin C. Severe varicella zoster pneumonia during the course of treatment with azathioprine for Crohn's disease. Rev Mal Respir 20 (2003) 773-776
134. Lyon C.C., and Thompson D. Herpes zoster encephalomyelitis associated with low dose methotrexate for rheumatoid arthritis. J Rheumatol 24 (1997) 589-591
135. Mouzas I.A., Greenstein A.J., Giannadaki E., Balasubramanian S., Manousos O.N., and Sachar D.B. Management of varicella infection during the course of inflammatory bowel disease. Am J Gastroenterol 92 (1997) 1534-1537
136. Shiroky J.B., Frost A., Skelton J.D., Haegert D.G., Newkirk M.M., and Neville C. Complications of immunosuppression associated with weekly low dose methotrexate. J Rheumatol 18 (1991) 1172-1175
137. Tougeron D., Mauillon J., and Tranvouez J.L. Severe varicella infection during treatment with infliximab for Crohn's disease. Gastroenterol Clin Biol 30 (2006) 1410-1413
138. Vonkeman H., ten Napel C., Rasker H., and van de Laar M. Disseminated primary varicella infection during infliximab treatment. J Rheumatol 31 (2004) 2517-2518
139. Babcock G.J., Decker L.L., Volk M., and Thorley-Lawson D.A. EBV persistence in memory B cells in vivo. Immunity 9 (1998) 395-404
140. Crawford D.H. Biology and disease associations of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci 356 (2001) 461-473
141. Ternak G., Szucs G., and Uj M. The serological signs of the Epstein-Barr virus (EBV) activity in the elderly. Acta Microbiol Immunol Hung 44 (1997) 133-140
142. Thompson M.P., and Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res 10 (2004) 803-821
143. Baldanti F., Grossi P., Furione M., Simoncini L., Sarasini A., Comoli P., et al. High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. J Clin Microbiol 38 (2000) 613-619
144. Reijasse D., Le Pendeven C., Cosnes J., Dehee A., Gendre J.P., Nicolas J.C., et al. Epstein-Barr virus viral load in Crohn's disease: effect of immunosuppressive therapy. Inflammatory bowel diseases 10 (2004) 85-90
145. Bauer C.C., Aberle S.W., Popow-Kraupp T., Kapitan M., Hofmann H., and Puchhammer-Stockl E. Serum Epstein-Barr virus DNA load in primary Epstein-Barr virus infection. J Med Virol 75 (2005) 54-58
146. Weinstock D.M., Ambrossi G.G., Brennan C., Kiehn T.E., and Jakubowski A. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant 37 (2006) 539-546
147. Torre D., and Tambini R. Acyclovir for treatment of infectious mononucleosis: a meta-analysis. Scand J Infect Dis 31 (1999) 543-547
148. Funch D.P., Walker A.M., Schneider G., Ziyadeh N.J., and Pescovitz M.D. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 5 (2005) 2894-2900
149. Garrido Serrano A., Perez Martin F., Guerrero Igea F.J., Galbarro Munoz J., and Palomo Gil S. Fatal infectious mononucleosis during azathioprine treatment in Crohn's disease. Gastroenterol Hepatol 23 (2000) 7-8
150. Posthuma E.F., Westendorp R.G., van der Sluys Veer A., Kluin-Nelemans J.C., Kluin P.M., and Lamers C.B. Fatal infectious mononucleosis: a severe complication in the treatment of Crohn's disease with azathioprine. Gut 36 (1995) 311-313
151. Dayharsh G.A., Loftus Jr. E.V., Sandborn W.J., Tremaine W.J., Zinsmeister A.R., Witzig T.E., et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 122 (2002) 72-77
152. Bai M., Katsanos K.H., Economou M., Kamina S., Balli C., Briasoulis E., et al. Rectal Epstein-Barr virus-positive Hodgkin's lymphoma in a patient with Crohn's disease: case report and review of the literature. Scand J Gastroenterol 41 (2006) 866-869
153. Brown S.L., Greene M.H., Gershon S.K., Edwards E.T., and Braun M.M. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis and rheumatism 46 (2002) 3151-3158
154. Codling B.W., Keighley M.R., and Slaney G. Hodgkin's disease complicating Crohn's colitis. Surgery 82 (1977) 625-628
155. Collins W.J. Malignant lymphoma complicating regional enteritis. Case report and review of the literature. Am J Gastroenterol 68 (1977) 177-181
156. Hecker R., Sheers R., and Thomas D. Hodgkin's disease as a complication of Crohn's disease. Med J Aust 2 (1978) 603
157. Juffermans N.P., Jager A., Kersten M.J., van Oers M.H., and Hommes D.W. Epstein-Barr virus-related lymphomas in patients with inflammatory bowel disease. Ned Tijdschr Geneeskd 149 (2005) 1859-1863
158. Kelly M.D., Stuart M., Tschuchnigg M., Turner J., and Tydd T. Primary intestinal Hodgkin's disease complicating ileal Crohn's disease. Aust N Z J Surg 67 (1997) 485-489
159. Krugmann J., Sailer-Hock M., Muller T., Gruber J., Allerberger F., and Offner F.A. Epstein-Barr virus-associated Hodgkin's lymphoma and legionella pneumophila infection complicating treatment of juvenile rheumatoid arthritis with methotrexate and cyclosporine A. Hum Pathol 31 (2000) 253-255
160. Kumar S., Fend F., Quintanilla-Martinez L., Kingma D.W., Sorbara L., Raffeld M., et al. Epstein-Barr virus-positive primary gastrointestinal Hodgkin's disease: association with inflammatory bowel disease and immunosuppression. Am J Surg Pathol 24 (2000) 66-73
161. Li S., and Borowitz M.J. Primary Epstein-Barr virus-associated Hodgkin disease of the ileum complicating Crohn disease. Arch Pathol Lab Med 125 (2001) 424-427
162. Liote F., Pertuiset E., Cochand-Priollet B., D'Agay M.F., Dombret H., Numeric P., et al. Methotrexate related B lymphoproliferative disease in a patient with rheumatoid arthritis. Role of Epstein-Barr virus infection. J Rheumatol 22 (1995) 1174-1178
163. Morrison P.D., and Whittaker M. A case of Hodgkin's disease complicating Crohn's disease. Clin Oncol 8 (1982) 271-272
164. Rutgeerts P., D'Haens G., Targan S., Vasiliauskas E., Hanauer S.B., Present D.H., et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117 (1999) 761-769
165. Salloum E., Cooper D.L., Howe G., Lacy J., Tallini G., Crouch J., et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 14 (1996) 1943-1949
166. Schwartz L.K., Kim M.K., Coleman M., Lichtiger S., Chadburn A., and Scherl E. Case report: lymphoma arising in an ileal pouch anal anastomosis after immunomodulatory therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 4 (2006) 1030-1034
167. Shaw J.H., and Mulvaney N. Hodgkin's lymphoma: a complication of small bowel Crohn's disease. Aust N Z J Surg 52 (1982) 34-36
168. Sivarajasingham N., Adams S.A., Smith M.E., and Hosie K.B. Perianal Hodgkin's lymphoma complicating Crohn's disease. Int J Colorectal Dis 18 (2003) 174-176
169. Vanbockrijck M., Cabooter M., Casselman J., Vanvuchelen J., Van Hoof A., and Michielssen P. Primary Hodgkin disease of the ileum complicating Crohn disease. Cancer 72 (1993) 1784-1789
170. Palefsky J. Human papillomavirus infection in HIV-infected persons. Top HIV Med 15 (2007) 130-133
171. Clifford G.M., Gallus S., Herrero R., Munoz N., Snijders P.J., Vaccarella S., et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366 (2005) 991-998
172. Dunne E.F., Nielson C.M., Stone K.M., Markowitz L.E., and Giuliano A.R. Prevalence of HPV infection among men: A systematic review of the literature. J Infect Dis 194 (2006) 1044-1057
173. Munoz N. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 19 (2000) 1-5
174. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 (2003) 518-527
175. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (2006) 1247-1255
176. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 (2005) 271-278
177. Arbyn M., and Dillner J. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. J Clin Virol 38 (2007) 189-197
178. Barnabas R.V., Laukkanen P., Koskela P., Kontula O., Lehtinen M., and Garnett G.P. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 3 (2006) e138
179. Markowitz L.E., Dunne E.F., Saraiya M., Lawson H.W., Chesson H., and Unger E.R. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56 (2007) 1-24
180. Sanders G.D., and Taira A.V. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 9 (2003) 37-48
181. Saslow D., Castle P.E., Cox J.T., Davey D.D., Einstein M.H., Ferris D.G., et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 57 (2007) 7-28
182. Bosch F.X., Rohan T., Schneider A., Frazer I., Pfister H., Castellsague X., et al. Papillomavirus research update: highlights of the Barcelona HPV 2000 international papillomavirus conference. J Clin Pathol 54 (2001) 163-175
183. Marais D.J., Sampson C.C., Urban M.I., Sitas F., and Wiliamson A.L. The seroprevalence of IgG antibodies to human papillomavirus (HPV) types HPV-16, HPV-18, and HPV-11 capsid-antigens in mothers and their children. J Med Virol 79 (2007) 1370-1374
184. Wang S.S., Schiffman M., Shields T.S., Herrero R., Hildesheim A., Bratti M.C., et al. Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica. Br J Cancer 89 (2003) 1248-1254
185. Schiffman M., Castle P.E., Jeronimo J., Rodriguez A.C., and Wacholder S. Human papillomavirus and cervical cancer. Lancet 370 (2007) 890-907
186. Wright Jr. T.C., Massad L.S., Dunton C.J., Spitzer M., Wilkinson E.J., and Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 11 (2007) 201-222
187. Uronis H.E., and Bendell J.C. Anal cancer: an overview. Oncologist 12 (2007) 524-534
188. Bhatia J., Bratcher J., Korelitz B., Vakher K., Mannor S., Shevchuk M., et al. Abnormalities of uterine cervix in women with inflammatory bowel disease. World J Gastroenterol 12 (2006) 6167-6171
189. Kane S., Khatibi B., and Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol 103 (2008) 631-636
190. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 61, April 2005. Human papillomavirus. Obstet Gynecol 105 (2005) 905-918
191. Petry K.U., Kochel H., Bode U., Schedel I., Niesert S., Glaubitz M., et al. Human papillomavirus is associated with the frequent detection of warty and basaloid high-grade neoplasia of the vulva and cervical neoplasia among immunocompromised women. Gynecol Oncol 60 (1996) 30-34
192. Kleinschmidt-DeMasters B.K., and Tyler K.L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353 (2005) 369-374
193. Langer-Gould A., Atlas S.W., Green A.J., Bollen A.W., and Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353 (2005) 375-381
194. Van Assche G., Van Ranst M., Sciot R., Dubois B., Vermeire S., Noman M., et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353 (2005) 362-368
195. FDA. Warns of safety concern regarding rituxan in new patient population. (Accessed December 2006 at http://www.fda.gov/bbs/topics/NEWS/2006/NEW01532.html).
196. Kharfan-Dabaja M.A., Ayala E., Greene J., Rojiani A., Murtagh F.R., and Anasetti C. Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature. Bone Marrow Transplant 39 (2007) 101-107
197. Koralnik I.J. Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name?. Ann Neurol 60 (2006) 162-173
198. Yousry T.A., Major E.O., Ryschkewitsch C., Fahle G., Fischer S., Hou J., et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354 (2006) 924-933
199. Berger J.R. Progressive multifocal leukoencephalopathy. Handb Clin Neurol 85 (2007) 169-183
200. Vulliemoz S., Lurati-Ruiz F., Borruat F.X., Delavelle J., Koralnik I.J., Kuntzer T., et al. Favourable outcome of progressive multifocal leucoencephalopathy in two patients with dermatomyositis. J Neurol Neurosurg Psychiatry 77 (2006) 1079-1082
201. Fiore A.E., Shay D.K., Haber P., Iskander J.K., Uyeki T.M., Mootrey G., et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recomm Rep 56 (2007) 1-54
202. Simonsen L., Taylor R.J., Viboud C., Miller M.A., and Jackson L.A. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 7 (2007) 658-666
203. Dengler T.J., Strnad N., Buhring I., Zimmermann R., Girgsdies O., Kubler W.E., et al. Differential immune response to influenza and pneumococcal vaccination in immunosuppressed patients after heart transplantation. Transplantation 66 (1998) 1340-1347
204. Duchini A., Hendry R.M., Nyberg L.M., Viernes M.E., and Pockros P.J. Immune response to influenza vaccine in adult liver transplant recipients. Liver Transpl 7 (2001) 311-313
205. Hayney M.S., Welter D.L., Francois M., Reynolds A.M., and Love R.B. Influenza vaccine antibody responses in lung transplant recipients. Prog Transplant 14 (2004) 346-351
206. Huang K.L., Armstrong J.A., and Ho M. Antibody response after influenza immunization in renal transplant patients receiving cyclosporin A or azathioprine. Infect Immun 40 (1983) 421-424
207. Mazzone P.J., Mossad S.B., Mawhorter S.D., Mehta A.C., Schilz R.J., and Maurer J.R. The humoral immune response to influenza vaccination in lung transplant patients. Eur Respir J 18 (2001) 971-976
208. Scharpe J., Evenepoel P., Maes B., Bammens B., Claes K., Osterhaus A.D., et al. Influenza vaccination is efficacious and safe in renal transplant recipients. Am J Transplant 8 (2008) 332-337
209. Soesman N.M., Rimmelzwaan G.F., Nieuwkoop N.J., Beyer W.E., Tilanus H.W., Kemmeren M.H., et al. Efficacy of influenza vaccination in adult liver transplant recipients. J Med Virol 61 (2000) 85-93
210. Mamula P., Markowitz J.E., Piccoli D.A., Klimov A., Cohen L., and Baldassano R.N. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 5 (2007) 851-856
211. Fomin I., Caspi D., Levy V., Varsano N., Shalev Y., Paran D., et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Annals of the rheumatic diseases 65 (2006) 191-194
212. Gelinck L.B., van der Bijl A.E., Beyer W.E., Visser L.G., Huizinga T.W., van Hogezand R.A., et al. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Annals of the rheumatic diseases 67 (2008) 713-716
213. Kapetanovic M.C., Saxne T., Nilsson J.A., and Geborek P. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxford) 46 (2007) 608-611
214. Melmed G.Y., Ippoliti A.F., Papadakis K.A., Tran T.T., Birt J.L., Lee S.K., et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 101 (2006) 1834-1840
215. Ryan J., Zoellner Y., Gradl B., Palache B., and Medema J. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries. Vaccine 24 (2006) 6812-6822
216. Willis B.C., Ndiaye S.M., Hopkins D.P., and Shefer A. Improving influenza, pneumococcal polysaccharide, and hepatitis B vaccination coverage among adults aged <65 years at high risk: a report on recommendations of the Task Force on Community Preventive Services. MMWR Recomm Rep 54 (2005) 1-11
217. Allen U.D., Aoki F.Y., and Stiver H.G. The use of antiviral drugs for influenza: recommended guidelines for practitioners. Can J Infect Dis Med Microbiol 17 (2006) 273-284
218. Stephenson I., Clark T.W., and Pareek M. Antiviral treatment and prevention of seasonal influenza: a comparative review of recommendations in the European Union. J Clin Virol 42 (2008) 244-248
219. Monto A.S., Fleming D.M., Henry D., de Groot R., Makela M., Klein T., et al. Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. J Infect Dis 180 (1999) 254-261
220. Nicholson K.G., Aoki F.Y., Osterhaus A.D., Trottier S., Carewicz O., Mercier C.H., et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 355 (2000) 1845-1850
221. Wallis R.S., Broder M.S., Wong J.Y., Hanson M.E., and Beenhouwer D.O. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38 (2004) 1261-1265
222. Kaur N., and Mahl T.C. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci 52 (2007) 1481-1484
223. Takeuchi T., Tatsuki Y., Nogami Y., Ishiguro N., Tanaka Y., Yamanaka H., et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Annals of the rheumatic diseases 67 (2008) 189-194
224. Colombel J.F. Adalimumab safety in Crohn's disease patients: open label maintenance following the GAIN and CHARM trials. Am J Gastroenterol 102 suppl 2 (2007) S496-S497
225. Boatright M.D., and Wang B.W. Clinical infection with Strongyloides sterocoralis following etanercept use for rheumatoid arthritis. Arthritis and rheumatism 52 (2005) 1336-1337
226. Scalzini A., Barni C., Stellini R., and Sueri L. Fatal invasive aspergillosis during cyclosporine and steroids treatment for Crohn's disease. Dig Dis Sci 40 (1995) 528
227. Arts J., D'Haens G., Zeegers M., Van Assche G., Hiele M., D'Hoore A., et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflammatory bowel diseases 10 (2004) 73-78
228. Kaur N., and Mahl T.C. Pneumocystis carinii pneumonia with oral candidiasis after infliximab therapy for Crohn's disease. Dig Dis Sci 49 (2004) 1458-1460
229. Ricart E., Panaccione R., Loftus E.V., Tremaine W.J., and Sandborn W.J. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. The American journal of gastroenterology 96 (2001) 722-729
230. Arend S.M., Kuijper E.J., Allaart C.F., Muller W.H., and Van Dissel J.T. Cavitating pneumonia after treatment with infliximab and prednisone. Eur J Clin Microbiol Infect Dis 23 (2004) 638-641
231. Hage C.A., Wood K.L., Winer-Muram H.T., Wilson S.J., Sarosi G., and Knox K.S. Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy. Chest 124 (2003) 2395-2397
232. Munoz P., Giannella M., Valerio M., Soria T., Diaz F., Longo J.L., et al. Cryptococcal meningitis in a patient treated with infliximab. Diagn Microbiol Infect Dis 57 (2007) 443-446
233. Murai H., Tokunaga H., Kubo I., Kawajiri M., Iwaki T., Taniwaki T., et al. Myeloradiculitis caused by Cryptococcus neoformans infection in a patient with ulcerative colitis: a neuropathological study. J Neurol Sci 247 (2006) 236-238
234. True D.G., Penmetcha M., and Peckham S.J. Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab. J Rheumatol 29 (2002) 1561-1563
235. Jain V.V., Evans T., and Peterson M.W. Reactivation histoplasmosis after treatment with anti-tumor necrosis factor alpha in a patient from a nonendemic area. Respir Med 100 (2006) 1291-1293
236. Lee J.H., Slifman N.R., Gershon S.K., Edwards E.T., Schwieterman W.D., Siegel J.N., et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis and rheumatism 46 (2002) 2565-2570
237. Nakelchik M., and Mangino J.E. Reactivation of histoplasmosis after treatment with infliximab. The American journal of medicine 112 (2002) 78
238. Wood K.L., Hage C.A., Knox K.S., Kleiman M.B., Sannuti A., Day R.B., et al. Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med 167 (2003) 1279-1282
239. Bernstein C.N., Kolodny M., Block E., and Shanahan F. Pneumocystis carinii pneumonia in patients with ulcerative colitis treated with corticosteroids. Am J Gastroenterol 88 (1993) 574-577
240. Quan V.A., Saunders B.P., Hicks B.H., and Sladen G.E. Cyclosporin treatment for ulcerative colitis complicated by fatal Pneumocystis carinii pneumonia. Bmj 314 (1997) 363-364
241. Scott A.M., Myers G.A., and Harms B.A. Pneumocystis carinii pneumonia postrestorative proctocolectomy for ulcerative colitis: a role for perioperative prophylaxis in the cyclosporine era? Report of a case and review of the literature. Dis Colon Rectum 40 (1997) 973-976
242. Sharma K., Rao P., Krishnamurthy P., Ali S.A., and Beck G. Pneumocystis carinii jiroveci pneumonia following infliximab infusion for Crohn disease: emphasis on prophylaxis. South Med J 100 (2007) 331-332
243. Stenger A.A., Houtman P.M., Bruyn G.A., Eggink H.F., and Pasma H.R. Pneumocystis carinii pneumonia associated with low dose methotrexate treatment for rheumatoid arthritis. Scand J Rheumatol 23 (1994) 51-53
244. Tai T.L., O'Rourke K.P., McWeeney M., Burke C.M., Sheehan K., and Barry M. Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology (Oxford) 41 (2002) 951-952
245. Takenaka R., Okada H., Mizuno M., Nasu J., Toshimori J., Tatsukawa M., et al. Pneumocystis carinii pneumonia in patients with ulcerative colitis. J Gastroenterol 39 (2004) 1114-1115
246. Poppers D.M., and Scherl E.J. Prophylaxis against Pneumocystis pneumonia in patients with inflammatory bowel disease: toward a standard of care. Inflammatory bowel diseases 14 (2008) 106-113
247. Green H., Paul M., Vidal L., and Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clinic proceedings 82 (2007) 1052-1059
248. DiRienzo A.G., van Der Horst C., Finkelstein D.M., Frame P., Bozzette S.A., and Tashima K.T. Efficacy of trimethoprim-sulfamethoxazole for the prevention of bacterial infections in a randomized prophylaxis trial of patients with advanced HIV infection. AIDS Res Hum Retroviruses 18 (2002) 89-94
249. De Castro N., Neuville S., Sarfati C., Ribaud P., Derouin F., Gluckman E., et al. Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study. Bone Marrow Transplant 36 (2005) 879-883
250. Campbell S., Travis S., and Jewell D. Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol 17 (2005) 79-84
251. Dye C., Scheele S., Dolin P., Pathania V., and Raviglione M.C. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. Jama 282 (1999) 677-686
252. Dye C., Watt C.J., Bleed D.M., Hosseini S.M., and Raviglione M.C. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. Jama 293 (2005) 2767-2775
253. Aberra F.N., Stettler N., Brensinger C., Lichtenstein G.R., and Lewis J.D. Risk for active tuberculosis in inflammatory bowel disease patients. Clin Gastroenterol Hepatol 5 (2007) 1070-1075
254. Remicade for IV injection. Package insert centocort inc: Melvern PA USA (2002)
255. Hamdi H., Mariette X., Godot V., Weldingh K., Hamid A.M., Prejean M.V., et al. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 8 (2006) R114
256. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 (2001) 1098-1104
257. Saliu O.Y., Sofer C., Stein D.S., Schwander S.K., and Wallis R.S. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 194 (2006) 486-492
258. Sichletidis L., Settas L., Spyratos D., Chloros D., and Patakas D. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 10 (2006) 1127-1132
259. Carmona L., Gomez-Reino J.J., Rodriguez-Valverde V., Montero D., Pascual-Gomez E., Mola E.M., et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis and rheumatism 52 (2005) 1766-1772
260. Broekmans J.F., Migliori G.B., Rieder H.L., Lees J., Ruutu P., Loddenkemper R., et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. Eur Respir J 19 (2002) 765-775
261. Hommes D.W., and van Deventer S.J. Infliximab therapy in Crohn's disease: safety issues. Neth J Med 61 (2003) 100-104
262. Jasmer R.M., Nahid P., and Hopewell P.C. Clinical practice. Latent tuberculosis infection. N Engl J Med 347 (2002) 1860-1866
263. Obrador A., Lopez San Roman A., Munoz P., Fortun J., and Gassull M.A. Consensus guideline on tuberculosis and treatment of inflammatory bowel disease with infliximab. Spanish Working Group on Crohn Disease and Ulcerative Colitis. Gastroenterol Hepatol 26 (2003) 29-33
264. Hernandez-Cruz B., Ponce-de-Leon-Rosales S., Sifuentes-Osornio J., Ponce-de-Leon-Garduno A., and Diaz-Jouanen E. Tuberculosis prophylaxis in patients with steroid treatment and systemic rheumatic diseases. A case-control study. Clin Exp Rheumatol 17 (1999) 81-87
265. van der Klooster J.M., Bosman R.J., Oudemans-van Straaten H.M., van der Spoel J.I., Wester J.P., and Zandstra D.F. Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med 29 (2003) 2327-2329
266. Iseman M.D. Treatment of multidrug-resistant tuberculosis. N Engl J Med 329 (1993) 784-791
267. Arundel C., and Lewis J.H. Drug-induced liver disease in 2006. Curr Opin Gastroenterol 23 (2007) 244-254
268. Lee W.M. Drug-induced hepatotoxicity. N Engl J Med 333 (1995) 1118-1127
269. Nolan C.M., Goldberg S.V., and Buskin S.E. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. Jama 281 (1999) 1014-1018
270. Vanhoof J., Landewe S., Van Wijngaerden E., and Geusens P. High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors. Annals of the rheumatic diseases 62 (2003) 1241-1242
271. Zabana Y., Domenech E., San Roman A.L., Beltran B., Cabriada J.L., Saro C., et al. Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy. Inflammatory bowel diseases 14 (2008) 1387-1391
272. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. Am J Respir Crit Care Med 172 (2005) 1169-1227
273. Rampton D.S. Preventing TB in patients with Crohn's disease needing infliximab or other anti-TNF therapy. Gut 54 (2005) 1360-1362
274. Takeno M., Murakami S., and Ishigatsubo Y. [Tuberculosis associated with anti-TNF therapy]. Nippon Rinsho 65 (2007) 1308-1313
275. Gomez-Reino J.J., Carmona L., and Angel Descalzo M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis and rheumatism 57 (2007) 756-761
276. Hatemi G., Melikoglu M., Fresko I., Masatlioglu S., Tascilar K., and Yazici H. Infliximab does not suppress the tuberculin skin test (purified protein derivative). J Rheumatol 34 (2007) 474-480
277. Yeh Y.P., Luh D.L., Chang S.H., Suo J., Chang H.J., and Chen T.H. Tuberculin reactivity in adults after 50 years of universal bacille Calmette-Guerin vaccination in Taiwan. Trans R Soc Trop Med Hyg 99 (2005) 509-516
278. Bocchino M., Matarese A., Bellofiore B., Giacomelli P., Santoro G., Balato N., et al. Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. Eur J Clin Microbiol Infect Dis 27 (2008) 907-913
279. Schoepfer A.M., Flogerzi B., Fallegger S., Schaffer T., Mueller S., Nicod L., et al. Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol 103 (2008) 2799-2806
280. Clark S.A., Martin S.L., Pozniak A., Steel A., Ward B., Dunning J., et al. Tuberculosis antigen-specific immune responses can be detected using enzyme-linked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease. Clin Exp Immunol 150 (2007) 238-244
281. Ewer K., Deeks J., Alvarez L., Bryant G., Waller S., Andersen P., et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 361 (2003) 1168-1173
282. Menzies D., Pai M., and Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 146 (2007) 340-354
283. Naseer A., Naqvi S., and Kampmann B. Evidence for boosting Mycobacterium tuberculosis-specific IFN-gamma responses at 6 weeks following tuberculin skin testing. Eur Respir J 29 (2007) 1282-1283
284. Piana F., Ruffo Codecasa L., Baldan R., Miotto P., Ferrarese M., and Cirillo D.M. Use of T-SPOT.TB in latent tuberculosis infection diagnosis in general and immunosuppressed populations. New Microbiol 30 (2007) 286-290
285. Raby E., Moyo M., Devendra A., Banda J., De Haas P., Ayles H., et al. The effects of HIV on the sensitivity of a whole blood IFN-gamma release assay in Zambian adults with active tuberculosis. PLoS ONE 3 (2008) e2489
286. Takahashi H., Shigehara K., Yamamoto M., Suzuki C., Naishiro Y., Tamura Y., et al. Interferon gamma assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administration. Rheumatol Int 27 (2007) 1143-1148
287. Mazurek G.H., Jereb J., Lobue P., Iademarco M.F., Metchock B., and Vernon A. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 54 (2005) 49-55
288. Matulis G., Juni P., Villiger P.M., and Gadola S.D. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Annals of the rheumatic diseases 67 (2008) 84-90
289. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 60 (2005) 800-805
290. Theis V.S., and Rhodes J.M. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther 27 (2008) 19-30
291. Targonski PV, Poland GA. Pneumococcal vaccination in adults: recommendations, trends, and prospects. Cleve Clin J Med 2007;74:401-406, 408-410, 413-404.
292. Blonski W., and Lichtenstein G.R. Safety of biologic therapy. Inflammatory bowel diseases 13 (2007) 769-796
293. Farah R., Lisitsin S., and Shay M. Bacterial meningitis associated with infliximab. Pharm World Sci 28 (2006) 123-125
294. Mandell G. Principles and practice of infectious diseases. 6th edn (2005), Elsevier
295. Elkayam O., Ablin J., and Caspi D. Safety and efficacy of vaccination against streptococcus pneumonia in patients with rheumatic diseases. Autoimmun Rev 6 (2007) 312-314
296. Elkayam O., Caspi D., Reitblatt T., Charboneau D., and Rubins J.B. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 33 (2004) 283-288
297. Kaine J.L., Kivitz A.J., Birbara C., and Luo A.Y. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 34 (2007) 272-279
298. Kapetanovic M.C., Saxne T., Sjoholm A., Truedsson L., Jonsson G., and Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 45 (2006) 106-111
299. Visvanathan S., Keenan G.F., Baker D.G., Levinson A.I., and Wagner C.L. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. J Rheumatol 34 (2007) 952-957
300. Armitage K., and Woodhead M. New guidelines for the management of adult community-acquired pneumonia. Curr Opin Infect Dis 20 (2007) 170-176
301. Mandell L.A., Wunderink R.G., Anzueto A., Bartlett J.G., Campbell G.D., Dean N.C., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44 Suppl 2 (2007) S27-S72
302. Sandford J. The Sandford guide to antimicrobial therapy (2006-2007)
303. Ritz M.A., and Jost R. Severe pneumococcal pneumonia following treatment with infliximab for Crohn's disease. Inflammatory bowel diseases 7 (2001) 327
304. Diederen B.M. Legionella spp. and Legionnaires' disease. The Journal of infection 56 (2008) 1-12
305. Accessed at http://www.ecdc.europa.eu/health_topics/Legionelllosis/Index.html.
306. Dixon W.G., Watson K., Lunt M., Hyrich K.L., Silman A.J., and Symmons D.P. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis and rheumatism 54 (2006) 2368-2376
307. Kohn A., Daperno M., Armuzzi A., Cappello M., Biancone L., Orlando A., et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther 26 (2007) 747-756
308. Li Gobbi F., Benucci M., and Del Rosso A. Pneumonitis caused by Legionella pneumoniae in a patient with rheumatoid arthritis treated with anti-TNF-alpha therapy (infliximab). J Clin Rheumatol 11 (2005) 119-120
309. Tubach F., Ravaud P., Salmon-Ceron D., Petitpain N., Brocq O., Grados F., et al. Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists. Clin Infect Dis 43 (2006) e95-e100
310. Wallis R.S., Broder M., Wong J., Lee A., and Hoq L. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 41 Suppl 3 (2005) S194-S198
311. Wondergem M.J., Voskuyl A.E., and van Agtmael M.A. A case of legionellosis during treatment with a TNFalpha antagonist. Scand J Infect Dis 36 (2004) 310-311
312. DuPont H.L. The growing threat of foodborne bacterial enteropathogens of animal origin. Clin Infect Dis 45 (2007) 1353-1361
313. Grassl G.A., and Finlay B.B. Pathogenesis of enteric Salmonella infections. Curr Opin Gastroenterol 24 (2008) 22-26
314. Bodey G.P., and Fainstein V. Infections of the gastrointestinal tract in the immunocompromised patient. Annu Rev Med 37 (1986) 271-281
315. Fu A., Bertouch J.V., and McNeil H.P. Disseminated Salmonella typhimurium infection secondary to infliximab treatment. Arthritis and rheumatism 50 (2004) 3049
316. Katsarolis I., Tsiodras S., Panagopoulos P., Giannitsioti E., Skarantavos G., Ioannidis T., et al. Septic arthritis due to Salmonella enteritidis associated with infliximab use. Scand J Infect Dis 37 (2005) 304-305
317. Makkuni D., Kent R., Watts R., and Clunie G. Two cases of serious food-borne infection in patients treated with anti-TNF-alpha. Are we doing enough to reduce the risk?. Rheumatology (Oxford) 45 (2006) 237-238
318. Netea M.G., Radstake T., Joosten L.A., van der Meer J.W., Barrera P., and Kullberg B.J. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. Arthritis and rheumatism 48 (2003) 1853-1857
319. Rijkeboer A., Voskuyl A., and Van Agtmael M. Fatal Salmonella enteritidis septicaemia in a rheumatoid arthritis patient treated with a TNF-alpha antagonist. Scand J Infect Dis 39 (2007) 80-83
320. Liu D., Lawrence M.L., Ainsworth A.J., and Austin F.W. Toward an improved laboratory definition of Listeria monocytogenes virulence. Int J Food Microbiol 118 (2007) 101-115
321. Aparicio A.G., Munoz-Fernandez S., Bonilla G., Miralles A., Cerdeno V., and Martin-Mola E. Report of an additional case of anti-tumor necrosis factor therapy and Listeria monocytogenes infection: comment on the letter by Gluck et al. Arthritis and rheumatism 48 (2003) 1764-1765 author reply 1765-1766
322. Bowie V.L., Snella K.A., Gopalachar A.S., and Bharadwaj P. Listeria meningitis associated with infliximab. Ann Pharmacother 38 (2004) 58-61
323. Gluck T., Linde H.J., Scholmerich J., Muller-Ladner U., Fiehn C., and Bohland P. Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases. Arthritis and rheumatism 46 (2002) 2255-2257 author reply 2257
324. Izbeki F., Nagy F., Szepes Z., Kiss I., Lonovics J., and Molnar T. Severe Listeria meningoencephalitis in an infliximab-treated patient with Crohn's disease. Inflammatory bowel diseases 14 (2008) 429-431
325. Kesteman T., Yombi J.C., Gigi J., and Durez P. Listeria infections associated with infliximab: case reports. Clin Rheumatol 26 (2007) 2173-2175
326. Slifman N.R., Gershon S.K., Lee J.H., Edwards E.T., and Braun M.M. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis and rheumatism 48 (2003) 319-324
327. Wing E.J., and Gregory S.H. Listeria monocytogenes: clinical and experimental update. J Infect Dis 185 Suppl 1 (2002) S18-S24
328. Yildiz O., and Doganay M. Actinomycoses and Nocardia pulmonary infections. Curr Opin Pulm Med 12 (2006) 228-234
329. Fabre S., Gibert C., Lechiche C., Jorgensen C., and Sany J. Primary cutaneous Nocardia otitidiscaviarum infection in a patient with rheumatoid arthritis treated with infliximab. J Rheumatol 32 (2005) 2432-2433
330. Singh S.M., Rau N.V., Cohen L.B., and Harris H. Cutaneous nocardiosis complicating management of Crohn's disease with infliximab and prednisone. Cmaj 171 (2004) 1063-1064
331. Vohra P., Burroughs M.H., Hodes D.S., Norton K.I., Kaufman D.M., LeLeiko N.S., et al. Disseminated nocardiosis complicating medical therapy in Crohn's disease. J Pediatr Gastroenterol Nutr 25 (1997) 233-235
332. Bouza E., Munoz P., and Alonso R. Clinical manifestations, treatment and control of infections caused by Clostridium difficile. Clin Microbiol Infect 11 Suppl 4 (2005) 57-64
333. Bulusu M., Narayan S., Shetler K., and Triadafilopoulos G. Leukocytosis as a harbinger and surrogate marker of Clostridium difficile infection in hospitalized patients with diarrhea. Am J Gastroenterol 95 (2000) 3137-3141
334. Issa M., Vijayapal A., Graham M.B., Beaulieu D.B., Otterson M.F., Lundeen S., et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 5 (2007) 345-351
335. Rodemann J.F., Dubberke E.R., Reske K.A., Seo da H., and Stone C.D. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 5 (2007) 339-344
336. Ananthakrishnan A.N., McGinley E.L., and Binion D.G. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 57 (2008) 205-210
337. Dallal R.M., Harbrecht B.G., Boujoukas A.J., Sirio C.A., Farkas L.M., Lee K.K., et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 235 (2002) 363-372
338. Lamontagne F., Labbe A.C., Haeck O., Lesur O., Lalancette M., Patino C., et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 245 (2007) 267-272
339. Boyce J.M., and Pittet D. Guideline for Hand Hygiene in Health-Care Settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Infect Control Hosp Epidemiol 23 (2002) S3-40
340. Eckstein B.C., Adams D.A., Eckstein E.C., Rao A., Sethi A.K., Yadavalli G.K., et al. Reduction of Clostridium Difficile and vancomycin-resistant Enterococcus contamination of environmental surfaces after an intervention to improve cleaning methods. BMC Infect Dis 7 (2007) 61
341. Mayfield J.L., Leet T., Miller J., and Mundy L.M. Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis 31 (2000) 995-1000
342. Wilcox M.H., Fawley W.N., Wigglesworth N., Parnell P., Verity P., and Freeman J. Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection. J Hosp Infect 54 (2003) 109-114
343. McFarland L.V. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 101 (2006) 812-822
344. Barbut F., Delmee M., Brazier J.S., Petit J.C., Poxton I.R., Rupnik M., et al. A European survey of diagnostic methods and testing protocols for Clostridium difficile. Clin Microbiol Infect 9 (2003) 989-996
345. Barbut F., Lalande V., Burghoffer B., Thien H.V., Grimprel E., and Petit J.C. Prevalence and genetic characterization of toxin A variant strains of Clostridium difficile among adults and children with diarrhea in France. J Clin Microbiol 40 (2002) 2079-2083
346. Brazier J.S., Stubbs S.L., and Duerden B.I. Prevalence of toxin A negative/B positive Clostridium difficile strains. J Hosp Infect 42 (1999) 248-249
347. Johnson S., and Gerding D.N. Clostridium difficile-associated diarrhea. Clin Infect Dis 26 (1998) 1027-1034 quiz 1035-1026
348. Oldfield III E.C. Clostridium difficile-associated diarrhea: risk factors, diagnostic methods, and treatment. Rev Gastroenterol Disord 4 (2004) 186-195
349. van den Berg R.J., Vaessen N., Endtz H.P., Schulin T., van der Vorm E.R., and Kuijper E.J. Evaluation of real-time PCR and conventional diagnostic methods for the detection of Clostridium difficile-associated diarrhoea in a prospective multicentre study. J Med Microbiol 56 (2007) 36-42
350. Meyer A.M., Ramzan N.N., Loftus Jr. E.V., Heigh R.I., and Leighton J.A. The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. J Clin Gastroenterol 38 (2004) 772-775
351. Mylonaki M., Langmead L., Pantes A., Johnson F., and Rampton D.S. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol 16 (2004) 775-778
352. Elliott B., Chang B.J., Golledge C.L., and Riley T.V. Clostridium difficile-associated diarrhoea. Intern Med J 37 (2007) 561-568
353. Bignardi G.E. Risk factors for Clostridium difficile infection. J Hosp Infect 40 (1998) 1-15
354. Monaghan T., Boswell T., and Mahida Y.R. Recent advances in Clostridium difficile-associated disease. Gut 57 (2008) 850-860
355. Yip C., Loeb M., Salama S., Moss L., and Olde J. Quinolone use as a risk factor for nosocomial Clostridium difficile-associated diarrhea. Infect Control Hosp Epidemiol 22 (2001) 572-575
356. Barbut F., Richard A., Hamadi K., Chomette V., Burghoffer B., and Petit J.C. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol 38 (2000) 2386-2388
357. Sunenshine R.H., and McDonald L.C. Clostridium difficile-associated disease: new challenges from an established pathogen. Cleve Clin J Med 73 (2006) 187-197
358. Owens R.C. Clostridium difficile-associated disease: changing epidemiology and implications for management. Drugs 67 (2007) 487-502
359. McFarland L.V., Elmer G.W., and Surawicz C.M. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 97 (2002) 1769-1775
360. Bricker E., Garg R., Nelson R., Loza A., Novak T., and Hansen J. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev (2005) CD004610
361. Zar F.A., Bakkanagari S.R., Moorthi K.M., and Davis M.B. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45 (2007) 302-307
362. Lagrotteria D., Holmes S., Smieja M., Smaill F., and Lee C. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clin Infect Dis 43 (2006) 547-552
363. Goodman M.J., and Truelove S.C. Intensive intravenous regimen for membranous colitis. British medical journal 2 (1976) 354
364. Hill D.R., Ericsson C.D., Pearson R.D., Keystone J.S., Freedman D.O., Kozarsky P.E., et al. The practice of travel medicine: guidelines by the Infectious Diseases Society of America. Clin Infect Dis 43 (2006) 1499-1539
365. Stallmach A., and Carstens O. Role of infections in the manifestation or reactivation of inflammatory bowel diseases. Inflammatory bowel diseases 8 (2002) 213-218
366. Powell S.J., and Wilmot A.J. Ulcerative post-dysenteric colitis. Gut 7 (1966) 438-443
367. Treacher D.F., and Jewell D.P. Yersinia colitis associated with Crohn's disease. Postgrad Med J 61 (1985) 173-174
368. Demicheli V., Jefferson T., Rivetti A., and Price D. Vaccines for measles, mumps and rubella in children. Cochrane Database Syst Rev (2005) CD004407
369. Chalmers A., Scheifele D., Patterson C., Williams D., Weber J., Shuckett R., et al. Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J Rheumatol 21 (1994) 1203-1206
370. Duchini A., Goss J.A., Karpen S., and Pockros P.J. Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols. Clin Microbiol Rev 16 (2003) 357-364
371. Herron A., Dettleff G., Hixon B., Brandwin L., Ortbals D., Hornick R., et al. Influenza vaccination in patients with rheumatic diseases. Safety and efficacy. Jama 242 (1979) 53-56
372. National immunization program CfDP. Guide to contraindications to vaccination. Accessed September2003 at http://www.cdc.gov/vaccines/pubs/downloads/b_contraindications_guide.pdf).
373. Gross T.P., Khurana R.K., Higgins T., Nkowane B.S., and Hirsch R.L. Vaccine-associated poliomyelitis in a household contact with Netherton's syndrome receiving long-term steroid therapy. The American journal of medicine 83 (1987) 797-800
374. Heijstek M.W., Pileggi G.C., Zonneveld-Huijssoon E., Armbrust W., Hoppenreijs E.P., Uiterwaal C.S., et al. Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. Annals of the rheumatic diseases 66 (2007) 1384-1387
375. Khan S., Erlichman J., and Rand E.B. Live virus immunization after orthotopic liver transplantation. Pediatr Transplant 10 (2006) 78-82
376. National Advisory Committee on Immunization (NACI) update on varicella. Can Commun Dis Rep 30 (2004) 1-26
377. Stevens R., Oliver M., Brogan M., Heiserodt J., and Targan S. Defective generation of tetanus-specific antibody-producing B cells after in vivo immunization of Crohn's disease and ulcerative colitis patients. Gastroenterology 88 (1985) 1860-1866
378. Abu-Shakra M., Press J., Varsano N., Levy V., Mendelson E., Sukenik S., et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol 29 (2002) 2555-2557
379. Holvast A., Huckriede A., Wilschut J., Horst G., De Vries J.J., Benne C.A., et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Annals of the rheumatic diseases 65 (2006) 913-918
380. Versluis D.J., Beyer W.E., Masurel N., Wenting G.J., and Weimar W. Impairment of the immune response to influenza vaccination in renal transplant recipients by cyclosporine, but not azathioprine. Transplantation 42 (1986) 376-379
381. de Roux A., Marx A., Burkhardt O., Schweiger B., Borkowski A., Banzhoff A., et al. Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients. Vaccine 24 (2006) 1537-1542
382. Silberman H., Overturf G.D., Field R.J., Butler J., Berne T.V., and Witt R. Response of renal allograft recipients to pneumococcal vaccine. Ann Surg 192 (1980) 199-201
383. de Roux A., Schmidt N., Rose M., Zielen S., Pletz M., and Lode H. Immunogenity of the pneumococcal polysaccharide vaccine in COPD patients. The effect of systemic steroids. Respir Med 98 (2004) 1187-1194
384. Kilhamn J., Lundin S.B., Brevinge H., Svennerholm A.M., and Jertborn M. T- and B-cell immune responses of patients who had undergone colectomies to oral administration of Salmonella enterica serovar Typhi Ty21a vaccine. Clin Diagn Lab Immunol 10 (2003) 426-430
385. Kilhamn J., Brevinge H., Svennerholm A.M., and Jertborn M. Immune responses in ileostomy fluid and serum after oral cholera vaccination of patients colectomized because of ulcerative colitis. Infect Immun 66 (1998) 3995-3999
386. Dumot J.A., Barnes D.S., Younossi Z., Gordon S.M., Avery R.K., Domen R.E., et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease. The American journal of gastroenterology 94 (1999) 1601-1604
387. Arslan M., Wiesner R.H., Poterucha J.J., and Zein N.N. Safety and efficacy of hepatitis A vaccination in liver transplantation recipients. Transplantation 72 (2001) 272-276
388. Gunther M., Stark K., Neuhaus R., Reinke P., Schroder K., and Bienzle U. Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients. Transplantation 71 (2001) 477-479
389. Steffen R., Rickenbach M., Wilhelm U., Helminger A., and Schar M. Health problems after travel to developing countries. J Infect Dis 156 (1987) 84-91
390. DuPont H.L., and Capsuto E.G. Persistent diarrhea in travelers. Clin Infect Dis 22 (1996) 124-128
391. Adachi J.A., Ericsson C.D., Jiang Z.D., DuPont M.W., Martinez-Sandoval F., Knirsch C., et al. Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico. Clin Infect Dis 37 (2003) 1165-1171
392. Cobelens F.G., van Deutekom H., Draayer-Jansen I.W., Schepp-Beelen A.C., van Gerven P.J., van Kessel R.P., et al. Risk of infection with Mycobacterium tuberculosis in travellers to areas of high tuberculosis endemicity. Lancet 356 (2000) 461-465
393. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 49 (2000) 1-51
394. Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep 54 (2005) 1-47
395. Jensen P.A., Lambert L.A., Iademarco M.F., and Ridzon R. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep 54 (2005) 1-141
396. Senay H., and MacPherson D. Parasitology: diagnostic yield of stool examination. Cmaj 140 (1989) 1329-1331
397. Thielman N.M., and Guerrant R.L. Persistent diarrhea in the returned traveler. Infect Dis Clin North Am 12 (1998) 489-501
398. Okhuysen P.C. Traveler's diarrhea due to intestinal protozoa. Clin Infect Dis 33 (2001) 110-114
399. Castelli F., Pezzoli C., and Tomasoni L. Epidemiology of travelers' diarrhea. J Travel Med 8 (2001) S26-30
400. Afzalpurkar R.G., Schiller L.R., Little K.H., Santangelo W.C., and Fordtran J.S. The self-limited nature of chronic idiopathic diarrhea. N Engl J Med 327 (1992) 1849-1852
401. Adedayo O., Grell G., and Bellot P. Hyperinfective strongyloidiasis in the medical ward: review of 27 cases in 5 years. South Med J 95 (2002) 711-716
402. Loutfy M.R., Wilson M., Keystone J.S., and Kain K.C. Serology and eosinophil count in the diagnosis and management of strongyloidiasis in a non-endemic area. Am J Trop Med Hyg 66 (2002) 749-752